<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646774</url>
  </required_header>
  <id_info>
    <org_study_id>ACN-MA-MYC-IA-2012</org_study_id>
    <nct_id>NCT02646774</nct_id>
  </id_info>
  <brief_title>Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis</brief_title>
  <official_title>A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma China, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of intravenous micafungin
      for the treatment of proven or probable fungal infections caused by Aspergillus sp.
      (Fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to administrative reasons
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall success rate for patients with no hematology disease</measure>
    <time_frame>At the end of the treatment (up to a maximum of 4 weeks)</time_frame>
    <description>Overall success rate = number of success patients/number of patients for efficacy evaluation x 100% at end of treatment (overall success is defined as patients with complete or partial response)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall success rate for patients with hematology disease</measure>
    <time_frame>At the end of the treatment (up to a maximum of 12 weeks)</time_frame>
    <description>Overall success rate = number of success patients/number of patients for efficacy evaluation x 100% at end of treatment (overall success is defined as patients with complete or partial response)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement rate for patients with no hematology disease</measure>
    <time_frame>Week 1 up to the end of the treatment (up to a maximum of 4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement rate for patients with hematology disease</measure>
    <time_frame>Week 1 up to the end of the treatment (up to a maximum of 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fungal clearance rate for patients with no hematology disease</measure>
    <time_frame>Week 1 up to the end of the treatment (up to a maximum of 4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fungal clearance rate for patients with hematology disease</measure>
    <time_frame>Week 1 up to the end of the treatment (up to a maximum of 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatality rate for patients with no hematology disease</measure>
    <time_frame>End of the treatment (up to 2 weeks, and up to 4 weeks for refractory patients)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatality rate for patients with hematology disease</measure>
    <time_frame>End of the treatment (up to 6 weeks, and up to 12 weeks for refractory patients)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with common Aspergillus infection sites</measure>
    <time_frame>End of treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by adverse events</measure>
    <time_frame>Up to 2 weeks after end of treatment (up to14 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Invasive Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Micafungin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micafungin</intervention_name>
    <description>Injection</description>
    <arm_group_label>Micafungin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are diagnosed as proven or probable infections caused by aspergillus
             (including fungemia, respiratory mycosis and gastrointestinal mycosis) with reference
             to the definition of EORTC/MSG

          -  Females of childbearing potential are not pregnant in the study and reliable methods
             of contraception should be maintained during the whole study.

          -  Patients capable to understand the purposes and risks of the study, who are willing
             and able to participate in the study and from whom written and dated informed consent
             to participate in the study is obtained.

        Exclusion Criteria:

          -  Patient received any echinocandins drug within 1 month prior to enrollment.

          -  Patient was enrolled in any other clinical study within the last month.

          -  AST/ALT &gt; 5 times the upper limit of normal (ULN)

          -  total bilirubin&gt; 2.5 times ULN

          -  BUN/Ccr &gt; 3 times ULN

          -  HIV positive patient

          -  Patient has a history of hypersensitivity, or any serious reaction to any component of
             this product or other echinocandins.

          -  Patient has a life expectancy of &lt;1 month

          -  Subject is unlikely to comply with the visits scheduled in the protocol in the opinion
             of investigator or has a history of non-compliance.

          -  Pregnant women, nursing mothers, lactating women, and women of child-bearing potential
             who are unwilling to use reliable contraception for the duration of the study and for
             6 weeks following completion of the study.

          -  Patient has been previously enrolled in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hengyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanchan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/study.aspx?ID=167</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspergillosis</keyword>
  <keyword>Antifungal</keyword>
  <keyword>Micafungin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

